Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by DryBoneson Oct 01, 2015 6:54pm
207 Views
Post# 24155210

RE:RE:HOW MANY PATIENTS REQUIRED

RE:RE:HOW MANY PATIENTS REQUIREDPILONG.  I didnt say any of those things you implied I said.  I pointed out merely that the number of patients for approval depends upon how successful the clinical trial results are.  We won't really know how many are needed until phase 2 is complete.  How many patients will be needed for phase 3 will be discussed with the FDA.  That is the process.  If phase 2 is marginal, it will require more patients, and better definition of type of patient and number of subjects.   if it is shows really good efficacy, then the number of patients is less. 
Bullboard Posts